FLUMADINE Drug Patent Profile

When do Flumadine patents expire, and when can generic versions of Flumadine launch?

Flumadine is a drug marketed by Forest Labs and Sun Pharm Inds Inc and is included in two NDAs.

The generic ingredient in FLUMADINE is rimantadine hydrochloride. There are three drug master file entries for this compound. One supplier is listed for this compound. Additional details are available on the rimantadine hydrochloride profile page.

DrugPatentWatch^® Litigation and Generic Entry Outlook for Flumadine

A generic version of FLUMADINE was approved as rimantadine hydrochloride by IMPAX LABS on August 30^th, 2002.

Summary for FLUMADINE

US Patents:	0
Applicants:	2
NDAs:	2

US Patents and Regulatory Information for FLUMADINE

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Forest Labs	FLUMADINE	rimantadine hydrochloride	SYRUP;ORAL	019650-001	Sep 17, 1993		DISCN	No	No
Sun Pharm Inds Inc	FLUMADINE	rimantadine hydrochloride	TABLET;ORAL	019649-001	Sep 17, 1993		DISCN	Yes	No

Investment and Fundamentals Analysis of Flumadine (Rimantadine)

Last updated: February 11, 2026

Overview
Flumadine (rimantadine) is an antiviral medication originally approved for the prophylaxis and treatment of influenza A virus infections. Its market presence has declined due to resistance issues and competition from newer antivirals. The drug's current regulatory status and market dynamics influence its investment profile and fundamental valuation prospects.

Regulatory Status and Patent Landscape

• FDA Approval: Flumadine received FDA approval in 1993 for influenza A prophylaxis and treatment.
• Patent Status: The original composition of matter patent expired in 2002, leading to generic manufacturing.
• Regulatory Exclusivity: No current patent exclusivity; no recent orphan drug or new chemical entity designations extend market protection.
• Market Authorization: While approved in some countries, regulatory retention varies globally, limiting immediate international expansion.

Market Dynamics and Sales Trends

• Historical Sales: Peak sales in the late 1990s exceeded $200 million annually in the US.
• Current Sales: Estimated below $10 million globally, mainly generic sales with limited Rx volume.
• Resistance and Efficacy: Influenza A resistance has risen significantly, reducing clinical utility. The CDC reports resistance levels exceeding 90%, curtailing prescriptions.
• Competitive landscape: Dominated by neuraminidase inhibitors (oseltamivir, zanamivir) and newer antivirals (baloxavir).

Commercial Viability

• Market Decay: The global influenza antiviral market shifts away from older drugs like rimantadine due to resistance and efficacy concerns.
• Off-label and Niche Uses: Rare; some research into multidrug-resistant influenza strains, but limited commercial interest.
• Regulatory Barriers: Reimbursement and prescribing are declining, making the drug less attractive for investment unless repositioning occurs.

Patents, Exclusivity, and R&D Opportunities

• Patent Expiration: 2002; no supplementary patents or formulations protecting Flumadine.
• R&D Prospects: Limited potential unless new formulations, delivery mechanisms, or combinations targeting resistant strains are developed.

Investment Outlook and Risks

• High Obsolescence Risk: Due to resistance and competition.
• Limited Market Magnetic: Most approvals have expired; sales unlikely to recover without innovation.
• Potential Niche Growth: Possible in research settings or for resistant strain treatment, but commercial landscape remains unfavorable.
• Liability of Off-Patent Status: Generics dominate; minimal revenue from original brand.

Key Drivers for Future Investment

• Discovery of new indications for resistant influenza strains.
• Development of derivatives or combination therapies that overcome resistance.
• Regulatory incentives for antiviral innovation, such as orphan drug status or accelerated approval pathways.

Financial Analysis Summary	Aspect	Current Status	Key Indicators
Revenue	Declined from $200+ million in the 1990s to <$10 million now	Market decline over 20 years
Patent/IP Protection	Expired in 2002, no current exclusivity	Elevated risk of generic competition
R&D Investment	Minimal; no ongoing clinical development	Limited pipeline, no upcoming trials
Market Position	Obsolete for most indications	Diminished market share, minimal growth

Key Takeaways
Flumadine's investment case is weak due to patent expiration, resistance-driven obsolescence, and a crowded competitive landscape with newer antivirals. R&D efforts might restore value if they produce innovative formulations or encounter activity against resistant strains. Without such developments, the asset offers limited upside and carries high risk of further market decline.

FAQs

1. What caused Flumadine's decline in market relevance?
   Resistance development and competition from newer, more effective antivirals.

2. Are there revived interest opportunities for Flumadine?
   Limited to niche research into resistant influenza strains; commercial prospects remain weak.

3. Can patent protections be re-established for Flumadine?
   No; patent expiration occurred in 2002. No secondary patents or formulations offer protection.

4. Is there any ongoing R&D for Flumadine?
   No significant clinical trials or development programs currently exist.

5. What regulatory incentives could aid Flumadine's revival?
   Potential orphan drug designation or accelerated approvals if new indications or formulations are demonstrated.

Sources
[1] U.S. Food and Drug Administration (FDA). Flumadine (rimantadine) approval history.
[2] CDC. Influenza antiviral resistance report.
[3] IMS Health. Pharmaceutical sales data (1990–2022).
[4] European Medicines Agency (EMA). Market approvals and status reports.
[5] Patent and regulatory filings.